⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4987 | 1.00 | — | — | |
| SCHEMBL847525 | 1.00 | — | — | |
| SCHEMBL8997410 | 0.97 | — | — | |
| SCHEMBL28148497 | 0.97 | — | — | |
| SCHEMBL27787678 | 0.97 | — | — | |
| Water SCHEMBL28050527 | 0.94 | — | — | |
| SCHEMBL28050663 | 0.91 | — | — | |
| SCHEMBL2186368 | 0.90 | — | — | |
| SCHEMBL28800 | 0.90 | — | — | |
| SCHEMBL3346843 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2023-12-21 | — | — | US | claimed |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2023-04-11 | — | — | US | claimed |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2022-09-22 | — | — | US | claimed |
| CN-112313234-B | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2022-04-29 | — | — | CN | claimed |
| US-20210198267-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-07-01 | — | — | US | claimed |
| CN-112313234-A | Pyrazolo-triazolopyrimidine derivatives as A2A receptor antagonists | 百济神州有限公司 | 2021-02-02 | — | — | CN | claimed |
| EP-3134408-B1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME (US) | 2020-08-12 | — | — | EP | claimed |
| US-10093683-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-09 | — | — | US | claimed |
| EP-3277675-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | 3-V Biosciences, Inc. (US) | 2018-02-07 | — | — | EP | claimed |
| CN-102118969-B | Diaminopyridine, diaminopyrimidine and diaminopyridazine modulators of the histamine H4 receptor | 詹森药业有限公司 | 2017-03-08 | — | — | CN | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| WO-2009152325-A1 | DIAMINO-PYRIDINE, PYRIMIDINE, AND PYRIDAZINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-17 | — | — | WO | claimed |
| EP-1989185-A1 | THERAPEUTIC COMPOUNDS | Helicon Therapeutics, Inc. (US) | 2008-11-12 | — | — | EP | claimed |
| US-7358250-B2 | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity | AMGEN INC. (US) | 2008-04-15 | — | — | US | claimed |
| WO-2007100851-A1 | THERAPEUTIC COMPOUNDS | HELICON THERAPEUTICS, INC. (US) | 2007-09-07 | — | — | WO | claimed |
| US-20070203154-A1 | Therapeutic Compounds | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-08-30 | — | — | US | claimed |
| EP-1768982-A2 | PYROLO [2,3-D] PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY | Amgen Inc. (US) | 2007-04-04 | — | — | EP | claimed |
| US-20060040965-A1 | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity | AMGEN INC. | 2006-02-23 | — | — | US | claimed |
| WO-2006004703-A2 | PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY | AMGEN INC. (US) | 2006-01-12 | — | — | WO | claimed |
| CN-1353713-A | Purine inhibitors of cyclin dependent kinase 2 and IK B-alpha | CV THERAPEUTICS INC (US) | 2002-06-12 | — | — | CN | claimed |